|Mr. Ronald K. Lloyd||CEO, Pres & Director||890.57k||N/A||1961|
|Dr. Darryl Roberts Ph.D.||Exec. VP of Operations & Product Devel.||468.24k||N/A||1961|
|Dr. Jerome Riebman FACC, M.A., M.D.||Chief Medical Officer||552.69k||N/A||1954|
|Mr. Matthew B. Ferguson||Chief Financial Officer||N/A||N/A||1968|
|Ms. Courtney Guyer||VP of Marketing||N/A||N/A||N/A|
|Mr. Thomas Englese||Chief Commercial Officer||N/A||N/A||1974|
|Mr. Jeffry D. Hamet||VP of Fin., Treasurer & Sec.||N/A||N/A||N/A|
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Aziyo Biologics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 8; Compensation: 7.